Guardant releases colorectal cancer blood test

2021 01 12 23 44 3780 Blood Test Samples Lab 400

Guardant Health has released a blood test for use in the U.S. to identify early colorectal cancer in average-risk adults. The company said that research supports the efficacy of its Shield test for early colon cancer detection.

In a validation effort using 309 patient samples (including 92 with colorectal cancer), the Shield test showed a sensitivity of 91% and a specificity of 92% for detecting colorectal cancer. It is intended for adults 45 years and older who are not current with screening recommendations, are asymptomatic, and are at average risk for the disease.

Page 1 of 5
Next Page